Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm 2 wound tissue of Erythropoietin and about 100-300 mg per cm 2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

1 . A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  wound tissue of Erythropoietin and about 100-300 μg per cm 2  wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject. 
     
     
         2 . A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby treating ischemia in the subject. 
     
     
         3 . The method of  claim 1 , wherein the connective tissue comprises collagen. 
     
     
         4 . The method of  claim 1 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         5 . The method of  claim 1 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 1 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         8 - 14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         16 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         17 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         18 . A unit dosage form comprising Erythropoietin at a dose of about 10-30 μg. 
     
     
         19 . A unit dosage form comprising Fibronectin at a dose of about 100-300 μg. 
     
     
         20 . A unit dosage form comprising Erythropoietin at a dose of about 10-30 μg and Fibronectin at a dose of about 100-300 μg. 
     
     
         21 . A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and a pharmaceutically acceptable carrier or diluent for topical administration. 
     
     
         22 . A pharmaceutical composition comprising as an active ingredient about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration. 
     
     
         23 . A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration. 
     
     
         24 - 26 . (canceled) 
     
     
         27 . A cosmetic composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and a cosmetically acceptable carrier or diluent. 
     
     
         28 . A cosmetic composition comprising as an active ingredient about 100-300 μg per ml Fibronectin and a cosmetically acceptable carrier or diluent. 
     
     
         29 . A cosmetic composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a cosmetically acceptable carrier or diluent. 
     
     
         30 - 31 . (canceled) 
     
     
         32 . A formulation, comprising:
 (i) as an active ingredient Erythropoietin and Fibronectin, wherein a concentration of said Erythropoietin is about 10-30 μg/mL and a concentration of said Fibronectin is about 100-300 μg/mL;   (ii) about 0.20% Methyl Paraben;   (iii) about 9% Laureth and Isoparafin and Polyacrylamide;   (iv) about 12% Deionized Water; and   (v) up to 100% Phosphate Buffer Solution.   
     
     
         33 . The method of  claim 2 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         34 . The method of  claim 2 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         35 . The method of  claim 2 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         36 . The method of  claim 2 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         37 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         38 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in separate formulations.